Sandoz has obtained commercial rights in Germany, the Netherlands and the UK to
Shionogi & Co's Rizmoic (naldemedine) novel treatment for constipation induced by opioid analgesics. The Novartis division also has right...
Sandoz Strikes Shionogi Partnership as Part of Pain Play
Listen to this article
By securing commercial rights to Shionogi’s Rizmoic drug for opioid-induced constipation, Sandoz is seeking to broaden its European pain treatments portfolio.
Stay ahead of every shift in generics and biosimilars.
More from Deals
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
